| P50 | author | Marta Roqué | Q28354251 |
| | Javier Zamora | Q37841600 |
| P2093 | author name string | David R Baldwin | |
| | Elise Hasler | |
| | Mia Schmidt-Hansen | |
| | Víctor Abraira | |
| P2860 | cites work | Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity | Q84064458 |
| | Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial | Q84132797 |
| | Reliability of positron emission tomography-computed tomography in identification of mediastinal lymph node status in patients with non-small cell lung cancer | Q84362372 |
| | A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer | Q84398281 |
| | Is mediastinoscopy still the gold standard to evaluate mediastinal lymph nodes in patients with non-small cell lung carcinoma? | Q84405984 |
| | The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer | Q84940362 |
| | [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax] | Q85912302 |
| | Concurrent chemoradiotherapy in non-small cell lung cancer | Q24234963 |
| | Surgery for local and locally advanced non-small cell lung cancer | Q24245182 |
| | QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies | Q27861031 |
| | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 |
| | Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews | Q29619492 |
| | Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging | Q31159102 |
| | Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer? | Q33704517 |
| | Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers | Q33914586 |
| | Fusion positron emission/computed tomography underestimates the presence of hilar nodal metastases in patients with resected non-small cell lung cancer | Q34201874 |
| | Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data | Q34279717 |
| | Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study | Q34288344 |
| | Impact of parenchymal tuberculosis sequelae on mediastinal lymph node staging in patients with lung cancer | Q34451922 |
| | Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis | Q35927554 |
| | Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging | Q36193014 |
| | Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study | Q36225895 |
| | Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study | Q36591008 |
| | Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer | Q36744525 |
| | The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients | Q36755418 |
| | Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. | Q36802864 |
| | Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. | Q36963307 |
| | FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications | Q37063199 |
| | Evaluation of pulmonary nodules and lung cancer with one-inch crystal gamma coincidence positron emission tomography/CT versus dedicated positron emission tomography/CT. | Q53353624 |
| | Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. | Q53365088 |
| | Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non-small cell lung cancer. | Q53377177 |
| | Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule. | Q53386784 |
| | Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. | Q53426186 |
| | Is palpation of the nonresected pulmonary lobe(s) required for patients with non-small cell lung cancer? A prospective study. | Q53437792 |
| | Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. | Q53442891 |
| | Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer. | Q53503060 |
| | The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers. | Q53510146 |
| | Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). | Q53523660 |
| | Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. | Q53539291 |
| | Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. | Q53566426 |
| | The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. | Q53613311 |
| | Contrast enhanced CT versus integrated PET-CT in pre-operative nodal staging of non-small cell lung cancer. | Q53654152 |
| | [Application of ¹⁸F-FDG PET/CT in pulmonary disease: a report of 419 cases]. | Q55464301 |
| | A unification of models for meta-analysis of diagnostic accuracy studies | Q56529110 |
| | A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations | Q74545500 |
| | Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients | Q79801720 |
| | Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer | Q79972519 |
| | Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer | Q80079357 |
| | Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial | Q81255947 |
| | [Comparing serum tumor antigen detection combined with CT scan with PET-CT for lung cancer diagnosis] | Q82233093 |
| | Integrated positron-emission tomography for nodal staging in lung cancer | Q82306989 |
| | Significance of PET/CT in determining actual TNM staging for patients with various lung cancers | Q82409331 |
| | Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer | Q83365028 |
| | A proposal for combined MRI and PET/CT interpretation criteria for preoperative nodal staging in non-small-cell lung cancer | Q83517552 |
| | Accuracy of positron emission tomography in mediastinal node assessment in coal workers with lung cancer | Q83548790 |
| | False-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable non-small cell lung cancer | Q83669646 |
| | [Utility of PET/CT for mediastinal staging of non-small cell lung cancer in stage III (N2)] | Q83939242 |
| | Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer | Q37087481 |
| | Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. | Q37105683 |
| | Measurement of primary tumor volume by PET-CT to evaluate risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes. | Q37392341 |
| | Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography | Q37493556 |
| | Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography | Q37821726 |
| | N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. | Q37934301 |
| | Evaluation of integrated positron emission tomography and computed tomography accuracy in detecting lymph node metastasis in patients with adenocarcinoma vs squamous cell carcinoma | Q38017971 |
| | Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer | Q38035192 |
| | LUCIS: lung cancer imaging studies | Q38061537 |
| | Repeatability of the Maximum Standard Uptake Value (SUVmax) in FDG PET. | Q38327306 |
| | Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT. | Q38494858 |
| | The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinom | Q39925547 |
| | Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer | Q42905272 |
| | Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? | Q43086231 |
| | Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. | Q43121444 |
| | Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer | Q43146024 |
| | Prediction of lymph node metastases in NSCLC. Three dimensional anatomical parameters do not substitute FDG-PET-CT. | Q43189162 |
| | Comparison between PET(-FDG) and computed tomography in the staging of lung cancer. Consequences for operability in 94 patients | Q43227425 |
| | Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers | Q43271272 |
| | Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q43413826 |
| | Advantages of diffusion-weighted imaging over positron emission tomography-computed tomography in assessment of hilar and mediastinal lymph node in lung cancer | Q43478685 |
| | Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection | Q43503660 |
| | Preoperative staging of lung cancer with combined PET-CT. | Q43608939 |
| | False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer | Q43981847 |
| | Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer | Q44113789 |
| | Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging | Q44318158 |
| | Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer | Q44464278 |
| | Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography | Q44483384 |
| | Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration | Q44529399 |
| | Non-small cell lung cancer: dual-modality PET/CT in preoperative staging | Q44598378 |
| | Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial | Q45656173 |
| | Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. | Q45919663 |
| | [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer]. | Q45926416 |
| | Positron emission tomography in staging early lung cancer: a randomized trial. | Q45937814 |
| | 18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. | Q46017040 |
| | The advantage of Positron Emission Tomography combined with Computer Tomography (PET-CT) in the diagnosis of lung cancer (experience with 408 patients) | Q46076383 |
| | The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax | Q46192851 |
| | Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer | Q46371252 |
| | Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease | Q46452298 |
| | Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection | Q46465924 |
| | Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. | Q46514376 |
| | Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results | Q46634592 |
| | Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. | Q46748277 |
| | STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients | Q46981366 |
| | Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis | Q47653945 |
| | The maximum standardized 18F-fluorodeoxyglucose uptake on positron emission tomography predicts lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer | Q48008565 |
| | Role of preoperative PET-CT in assessing mediastinal and hilar lymph node status in early stage lung cancer | Q48673504 |
| | Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. | Q51107428 |
| | Comparison of integrated positron emission tomography/computed tomography and mediastinoscopy in mediastinal staging of non-small cell lung cancer: analysis of 212 patients. | Q51324638 |
| | Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. | Q51744871 |
| | Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. | Q51926752 |
| | The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. | Q52850568 |
| | Is there any maximum standardized uptake value variation among positron emission tomography scanners for mediastinal staging in non-small cell lung cancer? | Q53082576 |
| | [Value of endobronchial ultrasound-transbronchial needle aspiration biopsy for diagnosis of PET-CT positive mediastinal lymph nodes]. | Q53132507 |
| | Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. | Q53153251 |
| | The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. | Q53163809 |
| | Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma. | Q53168604 |
| | Integrated PET/CT in non small cell lung cancer staging--clinical and pathological agreement. | Q53171800 |
| | [The value of extra-lung lesions on ¹⁸F-FDG PET/CT in improving diagnosis of lung cancer]. | Q53174968 |
| | Standard uptake value of positron emission tomography in clinical stage I lung cancer: clinical application and pathological correlation. | Q53182079 |
| | Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study. | Q53190429 |
| | Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal nodal staging of lung cancer. | Q53198788 |
| | Pattern and predictors of false positive lymph node involvement on positron emission tomography in patients with non-small cell lung cancer. | Q53211335 |
| | Efficacy of convex probe endobronchial ultrasound (CP-EBUS) assisted transbronchial needle aspiration for mediastinal staging in non-small cell lung cancer cases with mediastinal lymphadenopathy. | Q53217741 |
| | The validity of preoperative lymph node staging guidelines of European Society of Thoracic Surgeons in non-small-cell lung cancer patients. | Q53253440 |
| | Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. | Q53254546 |
| | Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer. | Q53267582 |
| | Incremental value of PET/CT Over CT for mediastinal nodal staging of non-small cell lung cancer: Comparison between patients with and without idiopathic pulmonary fibrosis. | Q53283281 |
| | [Value of positron emission tomography-computed tomography in the diagnosis of mediastinal lymph node metastasis of non-small cell lung cancer]. | Q53303181 |
| | Detection of nodal metastatic disease in patients with non-small cell lung cancer: comparison of positron emission tomography (PET), contrast-enhanced computed tomography (CT), and combined PET-CT. | Q53311656 |
| | Positron-emission tomography for lung cancer in a tuberculosis-endemic region. | Q53344718 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymph node | Q170758 |
| | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | CD009519 | |
| P577 | publication date | 2014-11-13 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer | |